(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Baidu robotaxi outage in Wuhan caused by 'system failure', police say - 2It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- 3Find the Lively Food Markets of South America
- 4FDA approves Wegovy pill for weight loss
- 5Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- 8 Espresso Bean Starting points All over the Planet
- Norovirus infections increase significantly, with positive test rates reaching 14%
- Investigating Free Cell Phones: What You Really want to Be aware
- Europe: 4 Urban communities for a Paramount Social Experience
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Ukraine's new defense minister just outlined how dire its troop shortage has become
- 'I was diagnosed with incurable brain cancer on holiday'
- Photos: Hundreds Gather at Bondi Beach After Deadly Attack
- Rescuers attempt to dig free whale stranded on Germany's Baltic coast
